The Federal Court of Australia accepted admissions by GlaxoSmithKline Consumer Healthcare Australia Pty Ltd and Novartis Consumer Health Australasia Pty Ltd that they made false or misleading representations in the marketing of Voltaren Osteo Gel and Voltaren Emulgel pain relief products. GSK and Novartis admitted that from January 2012 to March 2017 they marketed Osteo Gel as being specifically formulated and more effective than Emulgel in treating osteoarthritis related pain and inflammation. In fact, Osteo Gel and Emulgel products are essentially the same. An investigation by the Australian Competition and Consumer Commission (ACCC) found that, despite having the same active ingredients, Osteo Gel was often sold at a significantly higher retail price than Emulgel. A hearing will be held at a later date to determine penalties. (GSK acquired Novartis’ portfolio of Voltaren products in March 2016 and has been responsible for marketing and selling Voltaren products since that time.)